Eikon presents Phase 2 TeLuRide-005 EIK1001 data in stage 4 NSCLC at ASCO 2026

• Eikon Therapeutics on May 21, 2026 flagged six oncology abstracts that will be presented at the 2026 ASCO annual meeting starting May 29, 2026.
• Planned presentations highlight ongoing mid- to late-stage studies of EIK1001 in first-line stage 4 non-small cell lung cancer, including combinations with standard regimens, with an update focused on efficacy, safety, and immune-response profiling.
• Additional abstracts will outline early clinical progress for EIK1003 in advanced solid tumors, including combination use with paclitaxel, alongside updated monotherapy findings.
• EIK1005 updates will cover first-in-human safety and pharmacokinetics in healthy participants, with a separate trial design for use alone or with pembrolizumab in advanced solid tumors such as MSI-H or dMMR cancers.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eikon Therapeutics Inc. published the original content used to generate this news brief on May 21, 2026, and is solely responsible for the information contained therein.